Skip to main content

Table 2 Treatment data and efficacy of GEMCIS in unresectable gallbladder cancer

From: Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin

Variables N = 173
Treatment duration, months 3.8 ± 3.9
Total cycle 5.3 ± 4.4
OS, months (95% CI) 8.1 (7.1–10.2)
PFS, months (95% CI) 5.6 (4.5–6.8)
Best response
 CR 2 (1.2%)
 PR 26 (15.0%)
 SD 75 (43.4%)
 PD 48 (27.7%)
 NE 22 (12.7%)
ORR (CR + PR) 28 (16.2%)
DCR (CR + PR + SD) 103 (59.5%)
Number of cycles
 1 38 (22.0%)
 2 31 (18.0%)
 3 8 (4.7%)
 4 16 (9.3%)
 5 10 (5.8%)
 6 18 (10.5%)
 7 6 (3.5%)
 8 14 (8.1%)
 9 2 (1.2%)
  ≥ 10 30 (17.4%)
  1. GEMCIS gemcitabine plus cisplatin, OS overall survival, PFS progression-free survival, CI confidence interval, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate